Deciphering the selective androgen receptor modulators paradigm

  title={Deciphering the selective androgen receptor modulators paradigm},
  author={Xuqing Zhang and Zhihua Flemington Sui},
  journal={Expert Opinion on Drug Discovery},
  pages={191 - 218}
  • Xuqing Zhang, Z. Sui
  • Published 18 January 2013
  • Biology, Medicine
  • Expert Opinion on Drug Discovery
Introduction: The development and potential clinical use of tissue-selective androgen receptor modulators (SARMs) have advanced tremendously over the past few years. A key aspect of SARMs is the ability to clearly differentiate between the anabolic and androgenic activities. SARMs provide therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, end-stage renal disease, osteoporosis, frailty and hypogonadism. Areas covered: The aim of the… 

Androgen receptor modulators: a review of recent patents and reports (2012-2018)

Development of nonconventional AR-modulating agents targeting NTD and DBD, is likely to be a promising approach to develop multiple and synergistic strategies able to overcome any kind of androgen-dependent condition.

Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids

  • S. ChoiB. Lee
  • Biology, Medicine
    Expert opinion on drug safety
  • 2015
Based on the robust tissue selectivity of SARMs over AASs, they are worth considering as a promising therapeutic option for the treatment of various muscle-wasting diseases.

Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer

Enobosarm, a nonsteroidal SARM, is the most well characterized clinically, and has consistently demonstrated increases in lean body mass and better physical function across several populations along with a lower hazard ratio for survival in cancer patients.

Detection of SARMs in doping control analysis

Identification of Selected in vitro-Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control Purposes

The produced information enables the implementation of new target analytes into routine doping controls and expands the focus of anti-doping efforts concerning this new anabolic agent.

Human in vivo metabolism study of LGD-4033.

Analysis of the hydrolyzed as well as the non-hydrolyzed samples revealed that the two isomers of the dihydroxylated metabolite (M5) were preferred target metabolites, and the gluco-conjugated parent LGD-4033 and its glu Co-Conjugated metabolites M1 and M2 can be also considered as useful target analytes in non-Hydrolyzing samples.

Selective Androgen Receptor Modulators (SARMs) in Sports: A Review

Selective androgen receptor modulators (SARMs) are an exciting group of molecules with pronounced anabolic effects and very weak to missing androgenic ones and they tend to be a big promise for improving the treatment process in different socially significant diseases.

The cellular and molecular effects of the androgen receptor agonist , Cl-4 AS-1 , on breast cancer cells

Although Cl-4AS-1 has characteristics of classical AR agonist, it has dissimilar properties that may make it useful in treating breast cancer.



Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates

The patent literature focusing on SARMs is reviewed and reveals multiple chemical classes in various stages of preclinical and clinical development that suggest that SARMs will have a high level of clinical utility for a wide variety of health conditions.

Selective androgen receptor modulators in preclinical and clinical development

This review summarizes the current standing of research and development of Selective androgen receptor modulators, crystallography of AR with SARMs, plausible mechanisms for their action and the potential therapeutic indications for this emerging class of drugs.

Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.

This Award Address attempts to chronicle the landmark discoveries, organize the SARM landscape into clinically relevant bins, and provide insight into the clinical prospects for SARMs.

Improving selective androgen receptor modulator discovery and preclinical evaluation

The SARM field has advanced rapidly, but without a solid foundation of molecular knowledge to inform discovery and preclinical evaluation methods, which could lead to unforeseen and detrimental side effects with chronic administration of SARMs.

Recent developments in antiandrogens and selective androgen receptor modulators

Recent advances in the development of selective androgen receptor modulators

A new class of molecules targeting androgen receptors called selective androgen receptor modulators is being developed, analogous to the clinically successful and at present marketed selective estrogen receptors modulators.

Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands

TFM-4AS-1 and FTBU-1 represent two new classes of SARMs and will allow for comparative studies aimed at understanding the biophysical and physiological basis of tissue-selective effects of nuclear receptor ligands.

Discovery of the Selective Androgen Receptor Modulator MK-0773 Using a Rational Development Strategy Based on Differential Transcriptional Requirements for Androgenic Anabolism Versus Reproductive Physiology*

AR activated to moderate levels due to reduced cofactor recruitment, and N-/C-terminal interactions produce a fully anabolic response, whereas more complete receptor activation is required for reproductive effects.

Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.

The novel series of imidazolin-2-ones designed and synthesized as highly potent, orally active and muscle selective androgen receptor modulators (SARMs) are expected to provide beneficial anabolic effects on muscle with minimal androgenic effects on prostate tissue.

Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium.

  • A. Negro-Vilar
  • Biology, Medicine
    The Journal of clinical endocrinology and metabolism
  • 1999
Significant advances of hormone replacement therapy in postmenopausal females and the expansion and application of HRT to treat and prevent major disorders such as osteoporosis, cardiovascular disease, breast cancer, mood and cognition have clearly established the value of novel HRT therapies for improving women’s health, and by extrapolation, they clearly point out the potential for similar approaches to address men's health disorders.